Related Experiment Video
Updated: Jun 2, 2026
07:29
Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
Published on: June 20, 2015
Pharmacogenomics and cancer stem cells: a changing landscape?
Francesco Crea1, Maria Ana Duhagon, William L Farrar
1Department of Internal Medicine, Division of Pharmacology, University of Pisa, Pisa, Italy.
Trends in Pharmacological Sciences
|May 3, 2011
Summary
Pharmacogenomics in oncology can personalize cancer treatment by considering cancer stem cells (CSCs). Genetic variations in CSCs may predict patient response to anti-cancer drugs, improving therapy outcomes.
Area of Science:
- Oncology
- Pharmacogenomics
- Cancer Stem Cell Biology
Background:
- Pharmacogenomics aims to personalize cancer therapy but is limited by focusing on a few genes, yielding disappointing results in most cancers.
- Current pharmacogenomic studies often overlook the role of cancer stem cells (CSCs) in drug sensitivity and resistance.
- CSCs are a rare subpopulation in many cancers, and their specific genetic profiles can be masked by whole-tumor analysis.
Purpose of the Study:
- To review evidence on CSC chemoresistance and its link to genetic variations.
- To explore how genetic variations in CSC-related genes can predict individual responses to anti-cancer agents.
- To provide insights for designing future pharmacogenomic studies that incorporate CSC genetic profiling.
Main Methods:
- Literature review of current evidence on CSC chemoresistance.
- Analysis of genetic variations in CSC-related genes.
- Discussion of potential applications in pharmacogenomic study design.
Main Results:
- Genetic variations in CSC-related genes are implicated in chemoresistance.
- These variations may serve as predictive biomarkers for anti-cancer agent response.
- Current pharmacogenomic approaches may be insufficient due to neglecting CSCs.
Conclusions:
- Incorporating CSC genetic profiling into pharmacogenomics is crucial for advancing personalized cancer therapy.
- Future studies should focus on CSC-specific genetic variations to improve prediction of treatment outcomes.
- Understanding CSC biology is key to overcoming drug resistance in oncology.
Related Concept Videos
01:29Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
02:40Cancer Stem Cells and Tumor Maintenance
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
02:40Cancer Stem Cells and Tumor Maintenance
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...